Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases.
about
Molecular changes in hepatic metabolism and transport in cirrhosis and their functional importanceSystemic causes of cholestasisFXR signaling in the enterohepatic systemThe role of inflammation in cholestasis: clinical and basic aspectsInterleukin-1 beta-mediated suppression of RXR:RAR transactivation of the Ntcp promoter is JNK-dependentRegulation of MRP2/ABCC2 and BSEP/ABCB11 expression in sandwich cultured human and rat hepatocytes exposed to inflammatory cytokines TNF-{alpha}, IL-6, and IL-1{beta}Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver.Clinical application of transcriptional activators of bile salt transporters.Estrogen receptor alpha mediates 17alpha-ethynylestradiol causing hepatotoxicity.Medical treatment of cholestatic liver diseases: From pathobiology to pharmacological targets.The farnesoid X receptor: a novel drug target?Sodium-dependent bile salt transporters of the SLC10A transporter family: more than solute transporters.ATP8B1 gene expression is driven by a housekeeping-like promoter independent of bile acids and farnesoid X receptor.OATP8/1B3-mediated cotransport of bile acids and glutathione: an export pathway for organic anions from hepatocytes?Hepatocyte-specific ablation of Foxa2 alters bile acid homeostasis and results in endoplasmic reticulum stress.Human pharmacogenomic variations and their implications for antifungal efficacy.Cholestasis.Intestinal absorption of the bile acid analogue 75Se-homocholic acid-taurine is increased in primary biliary cirrhosis, and reverts to normal during ursodeoxycholic acid administration.Regulation of hepatic ABCC transporters by xenobiotics and in disease states.Interleukin-18 Down-Regulates Multidrug Resistance-Associated Protein 2 Expression through Farnesoid X Receptor Associated with Nuclear Factor Kappa B and Yin Yang 1 in Human Hepatoma HepG2 Cells.Elevated hepatic multidrug resistance-associated protein 3/ATP-binding cassette subfamily C 3 expression in human obstructive cholestasis is mediated through tumor necrosis factor alpha and c-Jun NH2-terminal kinase/stress-activated protein kinase-sThe ABC transporters MDR1 and MRP2: multiple functions in disposition of xenobiotics and drug resistance.Liver Expression of Sulphotransferase 2A1 Enzyme Is Impaired in Patients with Primary Sclerosing Cholangitis: Lack of the Response to Enhanced Expression of PXRDrug disposition alterations in liver disease: extrahepatic effects in cholestasis and nonalcoholic steatohepatitis.FXR: a target for cholestatic syndromes?FXR and PXR: potential therapeutic targets in cholestasis.Mechanisms of disease: mechanisms and clinical implications of cholestasis in sepsis.Comparative Localization and Functional Activity of the Main Hepatobiliary Transporters in HepaRG Cells and Primary Human Hepatocytes.Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.Nuclear receptors as therapeutic targets in cholestatic liver diseases.Sweroside ameliorates α-naphthylisothiocyanate-induced cholestatic liver injury in mice by regulating bile acids and suppressing pro-inflammatory responses.The role of FXR in disorders of bile acid homeostasis.Regulation of hepatic bile acid transporters Ntcp and Bsep expression.The state of cholesterol metabolism in the liver of patients with primary biliary cirrhosis: the role of MDR3 expression.Inhibition of P-glycoprotein, multidrug resistance-associated protein 2 and cytochrome P450 3A4 improves the oral absorption of octreotide in rats with portal hypertension.Transcriptional, Functional, and Mechanistic Comparisons of Stem Cell-Derived Hepatocytes, HepaRG Cells, and Three-Dimensional Human Hepatocyte Spheroids as Predictive In Vitro Systems for Drug-Induced Liver Injury.Hepatobiliary membrane transporters in primary biliary cirrhosis.Bile acid transporters and regulatory nuclear receptors in the liver and beyondNuclear receptor control of enterohepatic circulation.Intrahepatic cholestasis in common chronic liver diseases.
P2860
Q26769609-A51F4161-DF78-4ED9-8C05-548FC20022C5Q27008041-1DBD0CB9-72A9-404F-AECB-DE7BA20F8DD2Q27014753-99B2BCD1-9D68-4A4A-BABE-3EF38A5CA20EQ27694662-23DC0597-043F-4A59-B43C-D8CA68B9D070Q28569981-9DFF7EB5-30DD-4B2D-BDF6-54EE18AAC2D0Q28578667-E1248EAA-67EA-4135-A8C1-00E60C1E9696Q33480591-953B6568-C5A3-4D42-A258-E8FF6BC2C57FQ33709930-BE554E2B-C725-43AD-AB24-17BB5041C8A0Q33994966-BD12B30B-0882-423A-A220-85CA5CEFF8C2Q34017604-FA48B4AD-75E6-4642-827E-E85D482A9557Q34343494-FD1C1066-64A0-4971-A5B9-2261F14A599DQ34382931-A72F86D8-3FFB-4D9B-887F-19E466004A8FQ34517090-29E7E9A4-8233-4262-A4A0-9942C18A4695Q34552485-5FB85762-7457-48F1-9967-00288B5CFA3CQ34801719-F03798C2-4520-4C7C-BD40-C8BA60430365Q35070838-01D86DCB-1231-4BCA-94EE-889109822115Q35090225-92CFEA56-C568-447D-BEF6-27D0E2B09D58Q35595963-18B431D1-6432-489B-B676-E61C367BA483Q35690177-755D73FB-BE6E-4051-8D54-552E3F333D5CQ35751457-A83B8086-7BE4-412C-B953-C92A48A94C52Q35815498-D3BB3CD9-11E3-4A29-A7F9-3D6E2D8374B9Q35956193-A04D991D-F79A-4FC5-815E-B1F45C03F847Q36173223-6E2875EA-73B0-4BC9-B182-0DDC0CB75B0DQ36391044-2E33FB01-2A2D-4EB5-87F9-CF28E55E35C5Q36481061-A6AA1637-A612-4F09-90DE-FD5961757F1BQ36572561-6D9D49AB-B127-486C-B481-FA24CE4448F2Q36606886-46612100-2F6D-4BD7-863A-42DE2A903C22Q36801745-E1577599-DDA0-4EA3-9EA4-8A008A336A7EQ37121662-7FC4E396-DDF4-43B7-8332-14BAB7E816E4Q37230857-10F2512F-7504-4C24-90A2-B6081BB640D1Q37254611-E5754736-3D37-4959-8DB3-F42957170E02Q37300843-853CB9E2-4F15-4BAE-8746-C95BBF00A39EQ37339863-3D80A41B-616A-4868-B683-DCF2F3864466Q37356791-352BE4AD-968F-46D7-A223-0AAEF7C0BDCCQ37582128-F1DF7AC1-BCDF-44FB-B8D1-00FBD6392A2FQ37718523-EE0D1B4F-8679-4EA0-BECD-30BA77C22E8EQ37969179-F43A2686-2780-43B3-88BC-6067EA459104Q38033967-206BD3D5-117E-4357-8A4D-C7207A6D7736Q38110503-0D3036CF-4FEB-4D84-B36E-B956F6EAF11EQ38127461-93FB2E35-19AF-4CC3-8A77-395D815F4F17
P2860
Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Hepatobiliary transporter expr ...... th cholestatic liver diseases.
@en
Hepatobiliary transporter expr ...... th cholestatic liver diseases.
@nl
type
label
Hepatobiliary transporter expr ...... th cholestatic liver diseases.
@en
Hepatobiliary transporter expr ...... th cholestatic liver diseases.
@nl
prefLabel
Hepatobiliary transporter expr ...... th cholestatic liver diseases.
@en
Hepatobiliary transporter expr ...... th cholestatic liver diseases.
@nl
P2093
P50
P356
P1433
P1476
Hepatobiliary transporter expr ...... th cholestatic liver diseases.
@en
P2093
A Fuchsbichler
C Stumptner
K Zatloukal
R E Stauber
P304
P356
10.1053/JHEP.2001.22646
P407
P577
2001-03-01T00:00:00Z